ProMIS Neurosciences to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference
Provided By GlobeNewswire
Last update: Nov 3, 2025
Cambridge, Massachusetts, Nov. 03, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing next-generation therapies for Alzheimer’s disease (AD) and other neurodegenerative disorders, today announced that Neil Warma, Chief Executive Officer of ProMIS Neurosciences, and members of senior management will be participating in a fireside chat and investor one-on-one meetings at the Guggenheim 2nd Annual Healthcare Innovation Conference on Monday, November 10th, 2025 in Boston, MA.
Read more at globenewswire.com
